U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C27H43N3O4
Molecular Weight 473.648
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of TALTOBULIN

SMILES

CN[C@H](C(=O)N[C@H](C(=O)N(C)[C@H](\C=C(/C)C(O)=O)C(C)C)C(C)(C)C)C(C)(C)C1=CC=CC=C1

InChI

InChIKey=CNTMOLDWXSVYKD-PSRNMDMQSA-N
InChI=1S/C27H43N3O4/c1-17(2)20(16-18(3)25(33)34)30(10)24(32)22(26(4,5)6)29-23(31)21(28-9)27(7,8)19-14-12-11-13-15-19/h11-17,20-22,28H,1-10H3,(H,29,31)(H,33,34)/b18-16+/t20-,21-,22-/m1/s1

HIDE SMILES / InChI

Molecular Formula C27H43N3O4
Molecular Weight 473.648
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 3
E/Z Centers 1
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/18240145

Taltobulin, also known as HTI-286 and SPA-110, is a fully synthetic analog of the natural tripeptide hemiasterlin, inhibits tubulin polymerization and circumvents transport-based resistance to taxanes. Taltobulin was a potent inhibitor of proliferation (mean IC50 = 4 nm in 18 human tumor cell lines) and had substantially less interaction with multidrug resistance protein (P-glycoprotein) than currently used antimicrotubule agents, including paclitaxel, docetaxel, vinorelbine, or vinblastine. Taltobulin showed strong antitumor activity both in androgen-dependent and androgen- independent tumors and may be a promising agent in second- line treatment strategies for patients suffering from docetaxel- refractory prostate cancer.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: CHEMBL612799
2.0 nM [IC50]
0.3 µM [Kd]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Cells resistant to HTI-286 do not overexpress P-glycoprotein but have reduced drug accumulation and a point mutation in alpha-tubulin.
2004 Oct
Patents

Sample Use Guides

low dose (0.01 mg/mL), or high dose (0.05-0.125 mg/mL) Taltobulin prepared in PBS, intravesical treatment
Route of Administration: Other
Taltobulin was a potent inhibitor of proliferation in all tested bladder cancer cell lines at low nanomolar concentrations. The mean IC50 combining all cell lines was 4.0 +/- 2.1 nmol/L.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:40:40 GMT 2023
Edited
by admin
on Fri Dec 15 15:40:40 GMT 2023
Record UNII
J6D6912BXS
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TALTOBULIN
INN   USAN  
USAN   INN  
Official Name English
L-VALINAMIDE,N,.BETA.,.BETA.-TRIMETHYL-L-PHENYLALANINE-N-((1S,2E)-3-CARBOXY-1-(1-METHYLETHYL)-2-BUTENYL)-N,3-DIMETHYL
Common Name English
(4S)-4-[[(2S)-3,3-Dimethyl-2-[[(2S)-3-methyl-2-(methylamino)-3-phenylbutanoyl]amino]butanoyl]methylamino]-2,5-dimethylhex-2-enoic acid
Systematic Name English
HTI-286
Code English
TALTOBULIN [USAN]
Common Name English
taltobulin [INN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C67421
Created by admin on Fri Dec 15 15:40:40 GMT 2023 , Edited by admin on Fri Dec 15 15:40:40 GMT 2023
Code System Code Type Description
CAS
228266-40-8
Created by admin on Fri Dec 15 15:40:40 GMT 2023 , Edited by admin on Fri Dec 15 15:40:40 GMT 2023
PRIMARY
EPA CompTox
DTXSID2041040
Created by admin on Fri Dec 15 15:40:40 GMT 2023 , Edited by admin on Fri Dec 15 15:40:40 GMT 2023
PRIMARY
NCI_THESAURUS
C75998
Created by admin on Fri Dec 15 15:40:40 GMT 2023 , Edited by admin on Fri Dec 15 15:40:40 GMT 2023
PRIMARY
PUBCHEM
6918637
Created by admin on Fri Dec 15 15:40:40 GMT 2023 , Edited by admin on Fri Dec 15 15:40:40 GMT 2023
PRIMARY
USAN
OO-72
Created by admin on Fri Dec 15 15:40:40 GMT 2023 , Edited by admin on Fri Dec 15 15:40:40 GMT 2023
PRIMARY
SMS_ID
300000034410
Created by admin on Fri Dec 15 15:40:40 GMT 2023 , Edited by admin on Fri Dec 15 15:40:40 GMT 2023
PRIMARY
FDA UNII
J6D6912BXS
Created by admin on Fri Dec 15 15:40:40 GMT 2023 , Edited by admin on Fri Dec 15 15:40:40 GMT 2023
PRIMARY
INN
8454
Created by admin on Fri Dec 15 15:40:40 GMT 2023 , Edited by admin on Fri Dec 15 15:40:40 GMT 2023
PRIMARY
ChEMBL
CHEMBL182319
Created by admin on Fri Dec 15 15:40:40 GMT 2023 , Edited by admin on Fri Dec 15 15:40:40 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> DERIVATIVE
Related Record Type Details
ACTIVE MOIETY